- Record: found
- Abstract: not found
- Article: not found
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial
Andreas Schneeweiss ,
Volker Möbus ,
Hans Tesch ,
Claus Hanusch ,
Carsten Denkert ,
Kristina Lübbe ,
Jens Huober ,
Peter Klare ,
Sherko Kümmel ,
Michael Untch ,
Karin Kast ,
Christian Jackisch ,
Jörg Thomalla ,
Barbara Ingold-Heppner ,
Jens-Uwe Blohmer ,
Mahdi Rezai ,
Matthias Frank ,
Knut Engels ,
Kerstin Rhiem ,
Peter Andreas Fasching ,
Valentina Nekljudova ,
Gunter von Minckwitz ,
Sibylle Loibl
January 2019
January 2019
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
GeparOcto compared efficacy and safety of two chemotherapy regimens in high-risk early
breast cancer (BC): sequential treatment with intense dose-dense epirubicin, paclitaxel,
and cyclophosphamide (iddEPC) and weekly treatment with paclitaxel plus non-pegylated
liposomal doxorubicin (M, Myocet®) with additional carboplatin (PM(Cb)) in triple-negative
BC (TNBC).